News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AHF: Gilead Sciences, Inc. (GILD)’s $1,000 Hepatitis C Pill Target Of SF, NYC Protests Feb.12th



2/12/2014 9:52:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Advocates from AIDS Healthcare Foundation (AHF), the nation’s largest HIV/AIDS nonprofit medical provider, is spearheading two protests in New York City and San Francisco on Wednesday February 12th at 12 noon in each city targeting Gilead Sciences over the price of Sovaldi (sofosbuvir), its new Hepatitis C drug. The drug, which was approved by the Food and Drug Administration (FDA) in early December, was immediately priced by Gilead at $84,000 Wholesale Acquisition Cost (WAC) for a twelve-week supply of the drug—or $1,000 per pill.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES